Ngā hua rapu - Zhi‐Cheng Jing

Whakamahine hua
  1. 1
    Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak

    Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak mā Zhi‐Cheng Jing, Hua-Dong Zhu, Xiaowei Yan, Wen-Zhao Chai, Shuyang Zhang

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Experimental animal models of pulmonary hypertension: Development and challenges

    Experimental animal models of pulmonary hypertension: Development and challenges mā Xiaohan Wu, Jie‐Ling Ma, Dong Ding, Yuejiao Ma, Yunpeng Wei, Zhi‐Cheng Jing

    I whakaputaina 2022
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Burnout and Well-Being Among Medical Professionals in China: A National Cross-Sectional Study

    Burnout and Well-Being Among Medical Professionals in China: A National Cross-Sectional Study mā Ying Xiao, Dong Dong, Huanyu Zhang, Peipei Chen, Xiangyan Li, Zhuang Tian, Zhi‐Cheng Jing, Shuyang Zhang

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Protein O-GlcNAcylation in cardiovascular diseases

    Protein O-GlcNAcylation in cardiovascular diseases mā Hui‐Fang Wang, Yixuan Wang, Yu‐Ping Zhou, Yunpeng Wei, Yi Yan, Zejian Zhang, Zhi‐Cheng Jing

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Oestradiol ameliorates monocrotaline pulmonary hypertension<i>via</i>NO, prostacyclin and endothelin-1 pathways

    Oestradiol ameliorates monocrotaline pulmonary hypertension<i>via</i>NO, prostacyclin and endothelin-1 pathways mā Ping Yuan, Wenhui Wu, Lan Gao, Zeqi Zheng, Dong Liu, Han-Ying Mei, Zhuoli Zhang, Zhi‐Cheng Jing

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension

    The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension mā Youfei Fan, Rui Zhang, Xin Jiang, Li Wen, Danchen Wu, Dong Liu, Ping Yuan, Yulin Wang, Zhi‐Cheng Jing

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Publisher Correction: Pulmonary hypertension

    Publisher Correction: Pulmonary hypertension mā Ana Olga Mocumbi, Marc Humbert, Anitá Saxena, Zhi‐Cheng Jing, Karen Sliwa, Friedrich Thienemann, Stephen L. Archer, Simon Stewart

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Treatment algorithm for pulmonary arterial hypertension

    Treatment algorithm for pulmonary arterial hypertension mā Kelly Chin, Seán Gaine, Christian Gerges, Zhi‐Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, Olivier Sitbon

    I whakaputaina 2024
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension

    Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension mā Rong Jiang, Zisheng Ai, Xin Jiang, Ping Yuan, Dong Liu, Qin‐Hua Zhao, Jing He, Lan Wang, Mardi Gomberg‐Maitland, Zhi‐Cheng Jing

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients

    Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients mā Yanjie Hao, Xin Jiang, Wei Zhou, Yong Wang, Lan Gao, Yu Wang, Guangtao Li, Hong Tao, Yong Huo, Zhi‐Cheng Jing, Zhuoli Zhang

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension

    Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension mā Yuan Huang, Yiwei Liu, Haizhou Pan, Xiaoling Zhang, Jun Li, Xiang Li, Jian Meng, Peihe Wang, Jun Yang, Zhi‐Cheng Jing, Hao Zhang

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension

    Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension mā Danchen Wu, C. Conover Talbot, Qun Liu, Zhi‐Cheng Jing, Rachel L. Damico, Rubin M. Tuder, Kathleen C. Barnes, Paul M. Hassoun, Li Gao

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension

    Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension mā Zhi‐Cheng Jing, Xiaolu Jiang, Z-Y. Han, X-Q. Xu, Y. Wang, Yan Wu, H. Lv, C-R. Ma, YJ Yang, J-L. Pu

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Clinical features of paediatric pulmonary hypertension: a registry study

    Clinical features of paediatric pulmonary hypertension: a registry study mā Rolf M.F. Berger, Maurice Beghetti, Tilman Humpl, Gary E. Raskob, D. Dunbar Ivy, Zhi‐Cheng Jing, Damien Bonnet, Ingram Schulze‐Neick, Robyn J. Barst

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

    Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) mā Lewis J. Rubin, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Arno Fritsch, Flavia Menezes, Neil Davie, Hossein Ardeschir Ghofrani

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension

    Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-La... mā Gisela Meyer, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Lewis J. Rubin, Arno Fritsch, Neil Davie, Hossein Ardeschir Ghofrani

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Pulmonary function testing in patients with pulmonary arterial hypertension

    Pulmonary function testing in patients with pulmonary arterial hypertension mā Zhi‐Cheng Jing, Xi‐Qi Xu, David B. Badesch, Xin Jiang, Yan Wu, Jinming Liu, Yong Wang, Lei Pan, Huiping Li, Jielin Pu, Zhuoli Zhang, Yuejin Yang

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Lower Socioeconomic Status Is Associated with Worse Outcomes in Pulmonary Arterial Hypertension

    Lower Socioeconomic Status Is Associated with Worse Outcomes in Pulmonary Arterial Hypertension mā Wenhui Wu, Lu Yang, Fu-Hua Peng, Jing Yao, Liling Zou, Dong Liu, Xin Jiang, Jue Li, Lan Gao, Jieming Qu, Steven M. Kawut, Zhi‐Cheng Jing

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Riociguat for the Treatment of Pulmonary Arterial Hypertension

    Riociguat for the Treatment of Pulmonary Arterial Hypertension mā Hossein Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Michael Ochan Kilama, Arno Fritsch, D. Neuser, Lewis J. Rubin

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions

    Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions mā Babar Hasan, Georg Hansmann, Werner Budts, Alexandra Heath, Zahra Hoodbhoy, Zhi‐Cheng Jing, Martin Köestenberger, Katharina Meinel, Ana Olga Mocumbi, G. Radchenko, Hannes Sallmon, Karen Sliwa, Raman Kumar

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: